Company Overview - Zeling Bio has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors Jefferies and CICC [1] - The company is a late-stage clinical biotechnology firm focused on integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small molecule therapies [1] - Zeling Bio targets significant unmet medical needs in hematologic diseases, oncology, central nervous system disorders, and immune/inflammatory diseases, possessing eight proprietary assets in clinical and preclinical stages [1] Product Pipeline - The core product, Fluorotinib (FM), is in Phase 3 registration clinical trials for the treatment of myelofibrosis, a type of myeloproliferative neoplasm [1] - FM is a novel triple-target inhibitor of Janus kinase 2, FMS-like tyrosine kinase 3, and cyclin-dependent kinase 6 [1] - Another product, Pidilizumab (PM), is also in Phase 3 registration clinical trials for the treatment of relapsed/refractory diffuse large B-cell lymphoma, designed as a next-generation selective HDAC I/IIb inhibitor emphasizing selectivity and safety [1] Industry Insights - The global oncology therapeutics market is projected to grow from $262.1 billion in 2024 to $724.9 billion by 2035 [2] - The Chinese oncology therapeutics market is expected to expand from $37.2 billion in 2024 to $143.7 billion by 2035 [2] - The global myelofibrosis therapeutics market is anticipated to increase from $3 billion in 2024 to $11.1 billion by 2035, with a compound annual growth rate of 14.6% expected in the Chinese market during the same period [2]

Company Overview - Zeling Bio is a late-stage clinical biotechnology company focused on integrating structural biology, artificial intelligence, and clinically relevant disease models to develop highly differentiated small molecule therapies with first-in-class or best-in-class potential [4] - The company aims to address significant unmet medical needs in the fields of hematological diseases, oncology, central nervous system, and immune/inflammatory diseases [4] - As of January 5, 2026, Zeling Bio's pipeline includes two core products (Fluorotinib and Puyisitan injection), two clinical-stage candidates (ZL-82 and ZL-85), and four preclinical candidates (ZL-65, ZL-69, ZL-59, and ZL-89) [4] Product Details - Fluorotinib (FM) is a novel triple-target inhibitor for treating myeloproliferative neoplasms, including myelofibrosis and polycythemia vera, with a focus on JAK2V617F mutations [5] - Puyisitan (PM) is a next-generation selective HDAC I/IIb inhibitor designed to meet unmet medical needs, featuring a unique non-linear triangular cap structure that enhances binding affinity and selectivity compared to approved HDAC inhibitors [5] Financial Information - Zeling Bio has not yet received approval for any products for commercial sale and has not generated any revenue from product sales [7] - For the fiscal year ending December 31, 2024, and the nine months ending September 30, 2025, the company reported other income of RMB 19.66 million and RMB 7.13 million, respectively [8] - The company incurred operating losses of RMB 91.66 million for the fiscal year ending December 31, 2024, and RMB 119.04 million for the nine months ending September 30, 2025, primarily due to R&D expenses and changes in the redemption liability [7][8] Industry Overview - The global oncology drug market is projected to grow from USD 167 billion in 2020 to USD 262.1 billion by 2024, with a compound annual growth rate (CAGR) of 11.9%, and is expected to reach USD 724.9 billion by 2035 [9] - In China, the oncology drug market is expected to grow from USD 25.8 billion in 2020 to USD 37.2 billion by 2024, with a CAGR of 13.1%, reaching USD 143.7 billion by 2035 [9] - The global myelofibrosis drug market is anticipated to grow from USD 1.6 billion in 2020 to USD 3 billion by 2024, with a CAGR of 15.9%, and is projected to reach USD 11.1 billion by 2035 [13][16]

Core Viewpoint - Gaohong Pharmaceutical has officially submitted its listing application to the Hong Kong Stock Exchange, with a post-investment valuation of 2.462 billion RMB following its latest round of financing [2][10]. Financing and Valuation - The company has raised a total of 662 million RMB in financing since its establishment in 2017, with the latest Series C round contributing to its current valuation [2]. - The post-investment valuations for previous financing rounds are as follows: 264 million RMB for Series A, 500 million RMB for Series B, 1.001 billion RMB for Series B+, 1.3625 billion RMB for Series B2, 1.9503 billion RMB for Pre-C, and 2.462 billion RMB for Series C [3]. Product Pipeline and Development - The core product, TLL-018, is a highly selective JAK1/TYK2 inhibitor aimed at treating chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA), with plans to submit a New Drug Application (NDA) by the end of 2026 [8][9]. - The company is also exploring additional indications for TLL-018, including atopic dermatitis and systemic lupus erythematosus, indicating a broad market potential [8]. - Other products in the pipeline include TLL-041/BHV-8000 for neurodegenerative diseases and various HL series products targeting autoimmune and metabolic diseases [14]. Leadership and Expertise - Dr. Liang Congxin, the founder, is a renowned drug design expert with over 30 years of experience in new drug development, having contributed to the creation of several blockbuster drugs [4]. - The company's competitive edge lies in its proprietary kinase chemistry platform and a promising product pipeline, which together create significant technical barriers and market advantages [4][5]. Strategic Goals - The year 2026 is identified as a critical year for commercialization, with TLL-018 expected to be the company's first commercial product, marking a new revenue chapter [9]. - The company is pursuing global expansion through collaborations, such as with Biohaven for TLL-041, and has initiated clinical trials in the U.S. for other products [9].

Summary of Key Points from the Conference Call Industry Overview - The conference highlighted the significant advancements in China's innovative drug development, particularly in the oncology sector, showcased at the ASCO conference with a record number of presentations and reports [2][1]. Core Insights and Arguments - **Increased Global Competitiveness**: Chinese innovative drugs have shown remarkable improvement in global competitiveness, evidenced by a rise in high-value licensing agreements and a record number of presentations at ASCO, including 73 oral presentations and 11 LBA reports [2][1]. - **Significant Data from IBI363**: - IBI363, a second-generation IO product from Innovent Biologics, demonstrated a total survival rate (OS) exceeding 15 months in non-small cell lung cancer (NSCLC) patients, significantly outperforming existing therapies [6][10]. - In colorectal cancer, the 1 mg dose group achieved an OS of 17.5 months, nearing first-line treatment levels, with a disease control rate (DCR) exceeding 60% when combined with Bevacizumab [7][8]. - **Advancements in Dual Antibodies**: Companies like Innovent, Zai Lab, and 3SBio reported promising data in the dual antibody sector, particularly with IBI363 enhancing IL-2 functionality while reducing toxicity [3][1]. - **ADC and Small Molecule Innovations**: Companies such as Hengrui, Kelun, and Innovent showcased strong data in the ADC and small molecule therapy fields, indicating ongoing innovation in these advanced treatment modalities [5][1]. Noteworthy Developments - **Kangfang Biotech's Progress**: The PD-1 antibody, Cadonilimab, showed promising progression-free survival (PFS) rates of 12 months in patients with low PD-L1 expression, highlighting its potential in cervical cancer treatment [14][1]. - **Botai's ADC Drug Performance**: Botai's ADC drug 264 exhibited an overall response rate (ORR) of 45.1% in HER2 mutation-resistant patients, significantly higher than the control group [26][1]. - **Clinical Data from Other Companies**: - Companies like BeiGene and Maiwei Biotech presented data on ADCs and small molecules, demonstrating significant advancements in the treatment of various malignancies [16][1][17][1]. - The combination of Savolitinib and Osimertinib in NSCLC patients showed a PFS of 8.2 months, indicating a substantial improvement over chemotherapy [23][24]. Additional Important Insights - **Safety and Efficacy of IBI363**: Despite a treatment-related adverse event (TRAE) rate exceeding 40%, the main side effects were manageable, and the overall safety profile was deemed controllable [10][1]. - **Future Expectations for IBI363**: There is optimism regarding IBI363's future clinical data in first-line treatments and its safety profile in various indications, enhancing market confidence [9][1]. - **Emerging ADC Data**: Companies like LianTuo Biotech reported promising ADC data, with B7H3 ADC showing an ORR of 42.3% in CRPC patients [28][1]. This summary encapsulates the key points discussed during the conference call, focusing on the advancements in the Chinese pharmaceutical industry, particularly in oncology, and the promising data from various innovative therapies.